london euretina
retina race

Intravitreous anti-VEGF treatment compared with photocoagulation in retinopathy of prematurity (ROP)

Session Details

Session Title: Vascular Diseases and Diabetic Retinopathy IV

Session Date/Time: Sunday 20/09/2015 | 09:00-10:30

Paper Time: 09:08

Venue: Athena.

First Author: : J.Olea SPAIN

Co Author(s): :    J. Aragon              

Abstract Details

PURPOSE:To assess the efficacy of photocoagulation compared with intravitreous antiVEGF treatment in Retinopathy of Prematurity (ROP).

Setting:

Hospital Universitario Son Espases

Methods:

A retrospective , interventional, comparative non-randomized study was conducted. Three groups were studied: Group 1. Patients with ROP and treatment criteria, on whom antiVEGF intravitreous injections were administered. Group 2. . Patients with age and weight similar to group 1 chosen from the historical database from 1994-2009, treated with laser or cryotherapy. Group 3. Patients treated with a combination of laser and intravitreous anti-VEGF (less than 1 week between both techniques). A descriptive and comparative study of the incidence of mild/severe late stage ROP was made.

Results:

Group 1 antiVEGF. Twenty patients, with an average gestational age (GA) of 25.4 (1.1) w., average birth weight (BW) of 760.9 (172.8) gr. Treatment was administered at 12.9 (3.2) w. There was no mild/late stage ROP. Group 2 Laser. Eighty-six patients with an average GA of 25.9 (0.9) w., average BW of 807.5 (123.1) gr. Seven infants (8.1 %) showed signs of mild/late ROP. Group 3 Combined. Thirteen patients with an average GA of 26.1 (1.7) w., average BW of 754.2 (145.7) gr. Only one infant showed a mild macular ectopia in one eye. Although the incidence of complications is lower in the antiVEGF intravitreous group, there are no significant differences between groups.

Conclusions:

The efficacy of intravitreous antiVEGF injections in ROP is at least similar to classical laser treatment.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy